University of Miami Miller School of Medicine, USA
Dr. Barber is presently Chairman and Professor of the Department of Cell Biology at the University of Miami Miller School of Medicine (UMMSM), Miami, Florida, USA. He also holds the Eugenia J. Dodson Chair in Cancer Research at the UMMSM. Dr. Barber obtained his Ph.D from the Center for Applied Research and Microbiology (CAMR) and London University in 1989. After training at the University of Washington, Seattle, USA and the University of Tokyo, Japan, Dr. Barber became Assistant Professor at Emory University, Atlanta, USA in 1995.
View full bio
He has been at the UMMSM since 1999, where he discovered the cytosolic DNA, STING-dependent innate immune signaling pathway. Dr. Barber’s interests focus on innate immunity, infectious disease including HTLV1, inflammation and cancer as well as using viruses for the treatment of malignant disease.
Mayo Clinic, USA
Dr. Kennedy earned his B.S. degree in Microbiology from Brigham Young University and his Ph.D. in Immunology from Mayo Clinic with postdoctoral training in immunogenetics and vaccinology.
View full bio
Dr. Kennedy is the Co-Director of the Mayo Clinic Vaccine Research Group. Dr. Kennedy’s research emphasis is on understanding the factors driving the tremendous diversity in human immune responses to RNA viruses and viral vaccines. Of particular interest are emerging, re-emerging, and biodefense-related pathogens. His group focuses on the role of host genetic variation, age and immunosenescence, nutrition, and other factors on the development and maintenance of immunity following vaccination. The laboratory employs systems biology and vaccinomics approaches to better understand the complex interactions that occur during the development of vaccine response with the goal of predicting and controlling vaccine-induced immune responses and adverse events.
Since March 2019, responsible of the Discovery Performance Unit of the Italian Research & Development Center, leader in discovery and development of vaccines and human monoclonals.
View full bio
~20 years of experience in R&D with roles of increasing responsibility as Head of Mab discovery, as discovery and development project leader, managing highly diverse public-private partnerships. Externally recognized as a leader in vaccine R&D and novel breakthrough Monoclonal technologies.
Background: Microbiology, Biotechnology, Genetics, Molecular Biology and Immunology, Post-doctoral training at NIH, PhD work at the University of Delhi in India, degree in Genetics.
Poland Associates, USA
Caroline M. Poland is the Founder and President of Poland and Associates Consulting. She is a Licensed Mental Health Counselor, a Licensed Clinical Addictions Counselor, a Certified Clinical Trauma Professional, a Certified Compassion Fatigue Professional, and a Nationally Certified Counselor.
View full bio
She is also trained in EMDR therapy, a form of therapy designed for those who experience distress around traumatic memories and Post Traumatic Stress Disorder.
Ms. Poland is the creator of the Preferred Cognitive Styles and Decision Making Model, which was first discussed in a 2011 article published in Vaccine. This model outlines a series of cognitive styles that individuals employ in decision making, and outlines communication strategies that the health care provider can use to communicate effectively with that patient to create behavior change – in particular in regards to vaccine acceptance.
Ms. Poland is the former Director of the Counseling Center at Taylor University, where she held academic rank and designed and taught an innovative psychology class. She is a member of the Board of Advisors for the Vaccine Education Project, and was an invited participant for forums on vaccine hesitancy and acceptance through the American Academy of Arts and Sciences.
Ms. Poland has presented seminars and talks both nationally and internationally including invited talks at the United States Air Force Academy, Duke University, Mayo Clinic, Universidad Del Azuay in Cuenca, Ecuador, the University of Athens Children’s Hospital in Athens, Greece, the National Foundation for Infectious Diseases Annual Conference on Vaccine Research, the Annual Vaccine Congress, and the 4th Influenza Vaccines for the World Congress in Spain.
Ms. Poland has published numerous scientific papers and book chapters incorporating psychological and cognitive models into health decision making, specifically looking at vaccine hesitancy and acceptance.
Ms. Poland is a popular and energetic conference and seminar speaker, bringing insights from psychology, mental health, and science on the topics of vaccine hesitancy, compassion fatigue and burnout, trauma, establishing trauma informed educational, hospital, and clinical medical settings, sexual assault, emotional regulation, and improving overall health and wellness for flourishing.
Institut Pasteur de Guinée, Guinea/ Institut Pasteur, France
More information coming soon...
Emergent Biosolutions, USA
Kelly Lyn Warfield, Ph.D. is the Vice President of Vaccines Research and Development at Emergent BioSolutions. Dr. Warfield currently oversees a pipeline of vaccine candidates ranging from discovery through advanced development including recombinant viral vaccines, live attenuated bacterial vaccines, nanoparticle and virus-like particle (VLP) vaccines including the Phase 3 chikungunya VLP vaccine candidate.
View full bio
She has spent her career studying severe, acute viral infections by creating new animal models, developing novel vaccines and antivirals. Prior to joining Emergent, she was Senior Director, Antiviral Research at Unither Virology and led preclinical development of broad-spectrum antiviral candidates. Dr. Warfield was also previously the Vice President of Vaccine Development and a founder of Integrated Biotherapeutics with responsibility for overseeing advanced development of filovirus and staphylococcal vaccines and therapeutics. During a National Research Council postdoctoral fellowship at the United States Army Medical Research Institute of Infectious Diseases, she studied pathogenesis, developed animal models and candidate vaccines and therapeutics for hemorrhagic fever viruses including Ebola- and Marburgviruses. She has authored more than 80 peer-reviewed publications and multiple book chapters and is an inventor on over 15 patents/patent applications. Dr. Warfield received her Ph.D. degree in virology from Baylor College of Medicine and a B.S. in cellular and molecular biology from Loyola University in Maryland.
More speakers to follow...